Challenges for relative effectiveness assessment and early access of cancer immunotherapies in Europe

Challenges for relative effectiveness assessment and early access of cancer immunotherapies in Europe

Clinical endpoints relevant for relative effectiveness assessment (REA) reflect how patients feel, function, or survive. Outcome data requested by Health Technology Assessment (HTA) bodies in Europe to support reimbursement of an anticancer drug are based on final endpoints coming from completed com...

Full description

Bibliographic Details
Main Author:	Mira Pavlovic
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2016-11-01
Series:	Frontiers in Medicine
Subjects:	cancer immunotherapy relative effectiveness Endpoints Added benefit early access to market
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fmed.2016.00056/full

Similar Items

Alternative metrics for assessing clinical benefit with immunotherapy in oncology
by: E. Chan, et al.
Published: (2019-10-01)

Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases
by: Thomas Staab, et al.
Published: (2016-11-01)

Progression-Free Survival Early Assessment is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
by: Giuseppe Cabibbo, et al.
Published: (2021-12-01)

Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs
by: O. Pfaar, et al.
Published: (2020-04-01)

BorderChain: Blockchain-Based Access Control Framework for the Internet of Things Endpoint
by: Yustus Eko Oktian, et al.
Published: (2021-01-01)

Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients
by: Philip Bonomi, et al.
Published: (2019-10-01)

An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears
by: Nick Parsons, et al.
Published: (2019-12-01)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
by: Oriol Solà-Morales, et al.
Published: (2019-01-01)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
by: Shuang Zhang, et al.
Published: (2021-07-01)

Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe
by: Ildar Akhmetov, et al.
Published: (2015-06-01)

Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
by: Gita Bhat, et al.
Published: (2020-11-01)

Indonesia-Based Study of the Clinical and Cost-Saving Benefits of Subcutaneous Allergen Immunotherapy for Children with Allergic Rhinitis in Private Practice
by: Anang Endaryanto, et al.
Published: (2021-07-01)

Low doses in immunotherapy: Are they effective?
by: Vijay M Patil, et al.
Published: (2019-01-01)

Testing for Efficacy for Primary and Secondary Endpoints by Partitioning Decision Paths
by: Liu, Yi
Published: (2009)

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?
by: Yvonne Schuller, et al.
Published: (2018-11-01)

Grand Challenges in Allergen Immunotherapy
by: Linda Cox
Published: (2021-08-01)

Radiotherapy–immunotherapy combinations – perspectives and challenges
by: Michele Mondini, et al.
Published: (2020-07-01)

A Retrospective Database Analysis of Neonatal Morbidities to Evaluate a Composite Endpoint for Use in Preterm Labor Clinical Trials
by: Jeanne M. Pimenta, et al.
Published: (2018-01-01)

Patient Centered Outcomes in Periodontal Treatment-An Evidenced Based Approach
by: Ekta Bharatbhai Shah, et al.
Published: (2017-04-01)

Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities
by: Andriy Krendyukov
Published: (2020-09-01)

Computational Assessment of the Pharmacological Profiles of Degradation Products of Chitosan
by: Diana Larisa Roman, et al.
Published: (2019-09-01)

Monetary Valuation of Health Risks of Heavy Metals: State-of-the-art and some gaps
by: Ščasný M., et al.
Published: (2013-04-01)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
by: C. M. Dintsios, et al.
Published: (2019-12-01)

Food and Drug Administration approvals in phase 3 Cancer clinical trials
by: Joseph Abi Jaoude, et al.
Published: (2021-06-01)

Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies
by: Haipeng Zhu, et al.
Published: (2021-08-01)

Use of glucocorticoids in the management of immunotherapy‐related adverse effects
by: Hanping Wang, et al.
Published: (2020-10-01)

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology
by: Victoria J. Serpas, et al.
Published: (2018-12-01)

Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016
by: Gomon Yu.M., et al.
Published: (2017-08-01)

Evaluating multiple endpoints in heart failure clinical trials
by: Yang, Yijun
Published: (2016)

Surrogate endpoint evaluation using data from one large global randomized controlled trial
by: Milan Geybels, et al.
Published: (2021-05-01)

Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report
by: Chenxi Liu, et al.
Published: (2021-07-01)

EVENT-DRIVEN STUDIES AND SERIOUS CHRONIC DISEASES: ADDRESSING PLACEBO, DRUG EFFICACY, AND TREATMENT FAILURE IN PULMONARY ARTERY HYPERTENSION
by: Henning Gall, et al.
Published: (2014-10-01)

The Role of Customers’ Relationship Orientation in Perceiving Relational Benefits
by: Alireza Tourchian, et al.
Published: (2021-02-01)

Patient reported outcomes to support drug development decision making
by: Annabel Nixon, et al.
Published: (2015-06-01)

Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention—MACUSTAR
by: Jan H. Terheyden, et al.
Published: (2020-07-01)

Enhanced Efficacy of Sublingual Immunotherapy in Childhood Allergic Asthma by Probiotics
by: Anang Endaryanto, et al.
Published: (2018-04-01)

Long-term Efficacy of House Dust Mite Immunotherapy in Bronchial Asthma: A 15-year Follow-up Study
by: Wiqar A. Shaikh
Published: (2005-01-01)

Dogmas, challenges, and promises in phase III allergen immunotherapy studies
by: Pieter-Jan De Kam, PhD, et al.
Published: (2021-09-01)

Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy
by: Janina Köther, et al.
Published: (2018-07-01)

Early access programs: Benefits, challenges, and key considerations for successful implementation
by: Sanjaykumar Patil
Published: (2016-01-01)